An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

Inclusion Criteria:

Patients who have completed participation in 1 of the core studies in adult rheumatoid arthritis.

Exclusion Criteria:

Treatment with any investigational agent since the last administration of study drug in the core studies.
Treatment with iv gamma globulin, plasmapheresis, or prosorba column since the last administration of study drug in the core studies.
Treatment with an anti-TNF or anti-IL1 agent, a T-cell co-stimulation modulator, or any biologic since the last administration of study drug in the core studies.
Immunization with a live/attenuated vaccine since the last administration of study drug in the core studies.
Previous treatment with any cell-depleting therapies, including investigational agents.
Parenteral, intramuscular, or intra-articular corticosteroids within 6 weeks prior to baseline in this study.